TriSalus Life Sciences Confirms Positive Outlook For FY25 - Update

(RTTNews) - TriSalus Life Sciences Inc. (TLSI), an oncology focused medical technology company, Thursday reaffirmed its positive outlook for fiscal 2025.

For 2025, the company expects to be EBITDA positive and achieve positive cash flow by the second half of 2025, extending total cash runway beyond 2025.

Gross margins are expected to exceed 87 percent, and operating expenses are expected to decline greater than 20 percent in 2025.

Sales are expected to grow by more than 50 percent in 2025, driven by further market share increases in TriNav, the commercial launch of TriNav LV, and the TriNav target market expansion, among others.

Mary Szela, President and Chief Executive Officer of TriSalus Life Sciences, said, "We achieved commercial and clinical progress throughout 2024, and positioning TriSalus for greater success in 2025. We achieved $29.4 million in total revenue, marking 59 percent growth year-over-year, and continue to expect to deliver greater than 50 percent revenue growth in 2025. Additionally, we anticipate reducing operating expenses by more than 20 percent, achieving positive EBITDA for the full year, and achieving positive cash flow in the second half of the year."

In its fourth quarter, TriSalus reported narrower net loss compared to last year, amid higher revenues.

The company's bottom line came in at loss of $10.89 million or $0.40 per share, compared to loss of $36.44 million or $1.57 per share, last year.

The company's revenue for the period rose 44.4% to $8.26 million from $5.72 million last year.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.